id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-D-0756-0003,FDA,FDA-2021-D-0756,"Requests the FDA to extend the comment period for this Guidance by 90 days (150 days in total), or until May 23, 2022",Other,Electronic Regulation from Form,2022-02-17T05:00:00Z,2022,2,2022-09-01T04:00:00Z,,2025-01-07T17:17:35Z,,0,0,0900006484f814cf
FDA-2021-D-0756-0020,FDA,FDA-2021-D-0756,"Requests the FDA to extend the comment period for this Guidance by 90 days (150 days in total), or until May 23, 2022",Other,Electronic Regulation from Form,2022-02-11T05:00:00Z,2022,2,2022-09-01T04:00:00Z,,2025-01-07T17:17:52Z,,0,0,0900006484f6d615